Using PET imaging to predict immunotherapy success in lymphoma patients
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
This study is testing if PET scans can help predict how well immunotherapy works for patients with diffuse large B-cell lymphoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Drugs / interventions | immunotherapy, Glofitamab, CAR-T |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06755775 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how effective PET imaging targeting granzyme B can predict the outcomes for patients with diffuse large B-cell lymphoma (DLBCL) undergoing immunotherapy. Participants will be numbered and their medical records will be created, documenting essential information such as age, gender, and medical history. Each participant will undergo a PET scan using a 68Ga-grazytracer both at the start and after one course of immunotherapy, which may include CAR-T, Glofitamab, or iR2. The goal is to determine the correlation between granzyme B levels and treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with diffuse large B-cell lymphoma who are expected to survive for more than six months.
Not a fit: Patients with other malignant tumors or serious medical conditions that may affect their participation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify which patients are most likely to benefit from immunotherapy, leading to more personalized treatment plans.
How similar studies have performed: While the predictive value of PET imaging in immunotherapy is an emerging field, similar studies have shown promise in other cancers, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathologic diagnosis of DLBCL 2. Patient's general condition is good and survival is expected to be greater than six months 3. Signed and dated informed consent form Exclusion Criteria: 1. Combined with other malignant tumors 2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study 3. Pregnant women and women at risk of pregnancy, breastfeeding women 4. poor compliant
Where this trial is running
Shanghai
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Xinyi Zhu
- Email: zxy16zz@163.com
- Phone: 19121913585
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.